Download PDF
Semin Thromb Hemost 2001; 27(5): 537-542
DOI: 10.1055/s-2001-17964
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Clinical Monitoring of Hirudin and Direct Thrombin Inhibitors

Götz Nowak
  • Medical Faculty, Friedrich Schiller University Jena, Research Group ``Pharmacological Haemostaseology,'' Jena, Germany
Further Information

Publication History

Publication Date:
22 October 2001 (online)

    Permissions and Reprints

ABSTRACT

In addition to heparin, the standard medication for prophylaxis and therapy of thromboembolism, several other substances have been developed and tested for clinical use with the aim of decreasing or eliminating side effects. Most of all, hirudin, a direct antithrombin (AT), has proved to be effective. To define the therapeutic range and to avoid underdosage or overdosage, clinical monitoring is necessary. For monitoring of hirudin, thrombin time (TT) is not suited because of the missing linearity of the standard curve. Activated partial thromboplastin time (aPTT) can be used only in the lower hirudin level range, where the standard curve is quite linear. However, high and toxic hirudin levels cannot be determined using aPTT. Another drawback is a high variation in single measurements and in the normal value of patients. Methods using chromogenic substrates are suited for determination of hirudin in plasma but cannot be used at bedside. Especially for monitoring of hirudin, the ecarin clotting time (ECT) was developed. The standard curve is linear over the entire concentration range. There are no influences by other coagulation parameters or anticoagulants. For both acute clinical situations and long-term monitoring, this method capable of point-of-care therapy (POCT) will be the method of choice.

KEYWORD

Hirudin - ecarin clotting time - aPTT - thromboembolism

REFERENCES

  • 1 Griessbach U, Stuerzebecher J, Markwardt F. Assay of hirudin in plasma using a chromogenic thrombin substrate.  Thromb Res . 1985;  37 347-350
    CrossrefPubMedGoogle Scholar
  • 2 Spannagl M, Bichler J, Birg A, Lill H, Schramm W. Development of a chromogenic substrate assay for the determination of hirudin in plasma.  Blood Coagul Fibrinolysis . 1991;  2 121-127
    PubMedGoogle Scholar
  • 3 Nowak G, Bucha E, Brauns I, Czerwinski R. Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT II).  Wien Klin Wochenschr . 1997;  109/10 354-358
    PubMedGoogle Scholar
  • 4 Breddin H K, Radziwon P, Eschenfelder V, Müller-Peltzer H, Esslinger H U. PEG-hirudin and acetylsalicylic acid show a strong interaction on bleeding time.  Ann Hematol . 1996;  72 53(Abst)
    PubMedGoogle Scholar
  • 5 Pötzsch B, Iversen S, Riess F C. Recombinant hirudin as an anticoagulant in open-heart surgery: A case report.  Ann Hematol . 1994;  68(Suppl 2) A53(Abst)
    PubMedGoogle Scholar
  • 6 Walenga J M, Pifarré R. Hirudin as an anticoagulant in cardiopulmonary bypass. In: Pifarré R, ed. New Anticoagulants for the Cardiovascular Patient Philadelphia: Hanley & Belfus 1997: 175-186
    Google Scholar
  • 7 Nowak G, Bucha E. Quantitative determination of hirudin in blood and body fluids.  Semin Thromb Hemost . 1996;  22 197-202
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Nowak G, Bucha E, Hoffmann J. Verfahren zur Bestimmung von Hirudin und synthetischen Thrombininhibitoren. DPA 4203980.0 Deutsches Patentamt, 1992
    Google Scholar
  • 9 Tripodi A, Chantarangkul V, Arbini A A, Moia M, Manucci P M. Effects of hirudin on activated partial thromboplastin time determined with ten different reagents.  Thromb Haemost . 1993;  70 286-288
    PubMedGoogle Scholar